Microba Life Sciences Ltd - Asset Resilience Ratio

Latest as of December 2025: 11.53%

Microba Life Sciences Ltd (MAP) has an Asset Resilience Ratio of 11.53% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Microba Life Sciences Ltd debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

AU$5.00 Million
≈ $3.54 Million USD Cash + Short-term Investments

Total Assets

AU$43.35 Million
≈ $30.68 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how Microba Life Sciences Ltd's Asset Resilience Ratio has changed over time. See Microba Life Sciences Ltd net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Microba Life Sciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MAP market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$5.00 Million 11.53%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$5.00 Million 11.53%

Asset Resilience Insights

  • Moderate Liquidity: Microba Life Sciences Ltd has 11.53% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Microba Life Sciences Ltd Industry Peers by Asset Resilience Ratio

Compare Microba Life Sciences Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Revvity Inc.
NYSE:RVTY
Diagnostics & Research 0.00%
INTERGRATED DIA.H DL 025
F:8I8
Diagnostics & Research 7.34%
Immunovia publ AB
ST:IMMNOV
Diagnostics & Research 83.99%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%
Healius Ltd
AU:HLS
Diagnostics & Research 0.06%

Annual Asset Resilience Ratio for Microba Life Sciences Ltd (2018–2024)

The table below shows the annual Asset Resilience Ratio data for Microba Life Sciences Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 6.02% AU$2.85 Million
≈ $2.02 Million
AU$47.44 Million
≈ $33.56 Million
-1.60pp
2023-12-31 7.61% AU$4.42 Million
≈ $3.13 Million
AU$58.04 Million
≈ $41.07 Million
-19.28pp
2022-12-31 26.90% AU$12.63 Million
≈ $8.94 Million
AU$46.95 Million
≈ $33.22 Million
+25.86pp
2021-12-31 1.04% AU$408.88K
≈ $289.31K
AU$39.48 Million
≈ $27.93 Million
+0.49pp
2020-12-31 0.54% AU$100.60K
≈ $71.18K
AU$18.49 Million
≈ $13.08 Million
+0.08pp
2019-12-31 0.46% AU$49.77K
≈ $35.22K
AU$10.81 Million
≈ $7.65 Million
--
2018-12-31 0.00% AU$0.00
≈ $0.00
AU$13.99 Million
≈ $9.90 Million
--
pp = percentage points

About Microba Life Sciences Ltd

AU:MAP Australia Diagnostics & Research
Market Cap
$30.16 Million
AU$42.63 Million AUD
Market Cap Rank
#23803 Global
#937 in Australia
Share Price
AU$0.07
Change (1 day)
-9.09%
52-Week Range
AU$0.07 - AU$0.16
All Time High
AU$0.44
About

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the huma… Read more